secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001558370-24-004015
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics reports Q4/FY2023 cash $41.8M; Phase 3 uproleselan topline in Q2 2024
--------------------------------------------------------------------------------

- Cash and equivalents $41.8M at Dec 31, 2023, down from $47.9M at Dec 31, 2022.
- Phase 3 uproleselan topline results expected Q2 2024; NDA submission by end-2024 if positive.
- Phase 1a GMI-1687 met primary and secondary endpoints; research agreement with ASH RC for SCD.
- R&D expenses FY2023 $20.1M (down from $28.4M); G&A $19.2M (flat vs $19.1M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024004015/0001558370-24-004015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024004015/glyc-20240327x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer